LIQUIDIA Business Summary

Liquidia Corp (LQDA) is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of its lead product, YUTREPIA (treprostinil) inhalation powder, and a generic treprostinil injection marketed in partnership with Sandoz. The company’s business model is centered on its proprietary PRINT® technology, a particle engineering platform that enables the precise production of uniform drug particles for enhanced deep-lung delivery. Liquidia operates in two primary therapeutic segments: Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Following the full FDA approval and commercial launch of YUTREPIA in mid-2025, the company has rapidly captured approximately 25% of the inhaled treprostinil market as of early 2026. Its primary direct competitors include United Therapeutics (Tyvaso DPI), Insmed (TPIP), and Merck (Winrevair), with Liquidia positioning itself as a high-growth challenger offering a differentiated, dry-powder alternative to the long-standing incumbent therapies. Liquidia was founded by Dr. Joseph DeSimone, a renowned chemist and pioneer in nanotechnology. The current leadership team is led by CEO Dr. Roger Jeffs, who brings significant industry pedigree as the former co-CEO of United Therapeutics, where he oversaw the development of the very products Liquidia now competes against. Key executives include Michael Kaseta (COO & CFO), Dr. Rajeev Saggar (Chief Medical Officer), and Sanjeev Khindri (Chief Development Officer), who joined in 2025 to lead the expansion of the clinical pipeline, including the L606 extended-release formulation. The company is backed by notable institutional investors, including Patient Square Capital, which holds a significant stake, alongside Canaan Partners, New Enterprise Associates (NEA), and the Bill & Melinda Gates Foundation. The Board of Directors is chaired by Dr. Stephen Bloch and includes veteran industry leaders such as Arthur Kirsch and Paul Manning.